



## Cyltezo® (adalimumab-adbm) – First interchangeable biosimilar to Humira

- On October 18, 2021, the [FDA announced](#) the approval of [Boehringer Ingelheim's Cyltezo \(adalimumab-adbm\)](#), as the first interchangeable biosimilar to AbbVie's [Humira® \(adalimumab\)](#).
  - Cyltezo was originally approved as a biosimilar to Humira on August 25, 2017.
- Cyltezo and Humira share the following indications: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
- Humira is also indicated for hidradenitis suppurativa and uveitis.
  - These indications are protected by orphan drug exclusivity until approximately 2022 and 2023, respectively.
- The approval for interchangeability was supported by [VOLTAIRE-X](#), a 58-week, randomized switching study enrolling 238 patients with moderate-to-severe chronic plaque psoriasis. Patients received Humira and were then randomized to 'switching' or 'continuous' treatment.
  - Switching several times from Humira to Cyltezo produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity, and safety.
- Cyltezo is the first biosimilar product that has been granted interchangeability to Humira.
  - An interchangeable biosimilar product may be substituted for the reference product by the pharmacist without the intervention of the prescriber.
  - The substitution can occur at the pharmacy, a practice commonly called "pharmacy-level substitution"— much like how generic drugs are substituted for brand name drugs, subject to state pharmacy laws, which vary by state.
- Similar to Humira, Cyltezo carries a boxed warning for serious infections and malignancy.
- Boehringer Ingelheim has signed a patent settlement allowing commercial launch of Cyltezo on July 1, 2023. Cyltezo will be available as 40 mg/0.8 mL and 20 mg/0.4 mL in single-dose prefilled syringes



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.